BCRX
Price
$8.27
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
1.74B
52 days until earnings call
BEAM
Price
$20.88
Change
+$2.34 (+12.62%)
Updated
Sep 5 closing price
Capitalization
2.11B
64 days until earnings call
Interact to see
Advertisement

BCRX vs BEAM

Header iconBCRX vs BEAM Comparison
Open Charts BCRX vs BEAMBanner chart's image
BioCryst Pharmaceuticals
Price$8.27
Change-$0.00 (-0.00%)
Volume$3.09M
Capitalization1.74B
Beam Therapeutics
Price$20.88
Change+$2.34 (+12.62%)
Volume$4.72M
Capitalization2.11B
BCRX vs BEAM Comparison Chart in %
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. BEAM commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and BEAM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (BCRX: $8.27 vs. BEAM: $20.88)
Brand notoriety: BCRX: Notable vs. BEAM: Not notable
BCRX represents the Pharmaceuticals: Generic, while BEAM is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 103% vs. BEAM: 181%
Market capitalization -- BCRX: $1.74B vs. BEAM: $2.11B
BCRX [@Pharmaceuticals: Generic] is valued at $1.74B. BEAM’s [@Biotechnology] market capitalization is $2.11B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • BEAM’s FA Score: 1 green, 4 red.
According to our system of comparison, both BCRX and BEAM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while BEAM’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 3 bearish.
  • BEAM’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than BEAM.

Price Growth

BCRX (@Pharmaceuticals: Generic) experienced а -0.48% price change this week, while BEAM (@Biotechnology) price change was +27.63% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

BCRX is expected to report earnings on Oct 29, 2025.

BEAM is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.11B) has a higher market cap than BCRX($1.74B). BCRX YTD gains are higher at: 9.973 vs. BEAM (-15.806). BCRX has higher annual earnings (EBITDA): 63.4M vs. BEAM (-414.33M). BEAM has more cash in the bank: 1.15B vs. BCRX (260M). BEAM has less debt than BCRX: BEAM (155M) vs BCRX (703M). BCRX has higher revenues than BEAM: BCRX (558M) vs BEAM (60.3M).
BCRXBEAMBCRX / BEAM
Capitalization1.74B2.11B82%
EBITDA63.4M-414.33M-15%
Gain YTD9.973-15.806-63%
P/E RatioN/AN/A-
Revenue558M60.3M925%
Total Cash260M1.15B23%
Total Debt703M155M454%
FUNDAMENTALS RATINGS
BCRX: Fundamental Ratings
BCRX
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
PROFIT vs RISK RATING
1..100
78
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCRXBEAM
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 26 days ago
79%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
79%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
78%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ATGDX13.760.07
+0.51%
American Century International Gr R6
CIUEX13.200.03
+0.23%
Six Circles International Uncon Eq
MVGBX18.380.02
+0.11%
MFS Low Volatility Global Equity B
ARTNX17.93N/A
N/A
Artisan Select Equity Investor
FHJMX44.74N/A
N/A
Fidelity Advisor Europe I

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with CRNX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
N/A
CRNX - BCRX
41%
Loosely correlated
+3.97%
ETNB - BCRX
39%
Loosely correlated
+3.02%
BEAM - BCRX
39%
Loosely correlated
+12.62%
ROIV - BCRX
38%
Loosely correlated
+2.78%
VKTX - BCRX
38%
Loosely correlated
+1.70%
More

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+12.62%
CRSP - BEAM
66%
Closely correlated
+4.02%
NTLA - BEAM
63%
Loosely correlated
+3.79%
RXRX - BEAM
61%
Loosely correlated
+1.99%
SYRE - BEAM
57%
Loosely correlated
+0.06%
NRIX - BEAM
56%
Loosely correlated
+8.66%
More